CVM-1118
Phase 2Small molecule
CVM-1118 is one of 43 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
CVM-1118
TTaiRx, Inc.
Phase 2
Coreg
Akero TherapeuticsPreclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CVM-1118. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTaiRx, Inc.